Historically, the wide range of symptoms associated with fibromyalgia and the lack of a definitive diagnostic test have made it hard to identify the disease. Doctors needed to eliminate other possibilities before diagnosing fibromyalgia, a process that can take years to complete and cost tens of thousands of dollars. Not surprisingly, an estimated three out of four people with fibromyalgia remain undiagnosed today. The FM/a® Test is changing all that.
The patented FM/a® Test, owned by EpicGenetics, Inc., is the first and currently the only definitive blood test to objectively diagnose fibromyalgia. It is the result of award-winning research and independent clinical studies performed at the University of Illinois College of Medicine.
Since 2013, the FM/a® fibromyalgia blood test has successfully diagnosed thousands of patients and has a 99% accuracy rate.
The FM/a® Test was developed under the leadership of Bruce S. Gillis, M.D., M.P.H. Dr. Gillis has held faculty positions both at the University of California, Los Angeles and the University of Illinois College of Medicine at Chicago. For the past several years he has maintained active research programs at multiple university medical centers.
In September, 2021 Dr. Gillis was granted another US patent for a new mycobacterium-based protocol designed to address the underlying immuno-deficiencies found in those who suffer from Fibromyalgia. This marks an important milestone in the quest to not just identify the cause, but to also find sollutions to Fibromyalgia.